Abstract Background Inflammatory Bowel Disease (IBD), comprising Ulcerative Colitis (UC) and Crohn's Disease (CD), is a chronic inflammatory disorder characterized by dysregulated immune responses. Chemokines, which play crucial roles in immune regulation, have been implicated in the pathogenesis of IBD. However, the specific function of CXCR7 in IBD pathology remains largely unexplored. In this study, we investigated the therapeutic potential of our newly developed CXCR7 agonist in a preclinical IBD animal model. Methods Female C57BL/6J mice were divided into normal, model vehicle, 2 doses of IL21120033 (30, 60 mg/kg), and a positive control group (Cyclosporine A), each with 8-10 mice. Colitis was induced by 2% DSS administration in drinking water for 6 days followed by regular water for 3 days. Vehicle or test compound were administered orally once daily from Day 0-9. The disease activity index (DAI) was measured every day. Following the 9-day treatment period, animals were euthanized and colons were harvested for gross anatomical measurements. Longitudinally bisected colon specimens were either fixed for histopathological evaluation or cryopreserved at -80°c for subsequent IL-6 gene expression analysis. Results IL21120033 treatment significantly reduced DAI by 25% and 39% at 30 and 60 mg/kg, respectively. Both colon weight and length showed significant improvement compared to the model vehicle group. Histopathological analysis revealed decreased inflammation scores in IL21120033-treated groups. IL-6 mRNA expression demonstrated dose-dependent reduction following IL21120033 treatment. Conclusion IL21120033 demonstrated significant therapeutic efficacy in DSS-induced colitis, representing the first CXCR7 agonist showing beneficial effects in IBD. These findings suggest CXCR7 as a potential therapeutic target for IBD treatment.
Read full abstract